Abeona Therapeutics Inc

ABEONASDAQ

Trade with Public

$2.15

-0.15-6.33%

最終更新: Nov 13, 12:11 PM

概要ニュースチャート業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

決算: Q3 2026に発表されました。期中月 11 9thに決算が発表されました月 11 9th マーケットオープン前。

M&A: Ellodi Pharmaceuticals sold assets to Abeona Therapeutics (ABEO) on Monday, November 9, 2026 for $30M

Abeona Therapeutics (ABEO) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Abeona Therapeutics (ABEO) stock.

Analyst Consensus — 5 Analysts

5Buy

# Analysts5

Latest Upgrades and Downgrades for Abeona Therapeutics Stock

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$20→$18
—	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$30→$19
—	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$28→$30
—	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$17
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$22→$21
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$19→$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
—	Oppenheimer	Andreas Argyrides	Assumes	Outperform	$19
—	Stifel	Dae Gon Ha	PT Cut	Buy	$21→$20
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$15→$20
—	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$15
—	Oppenheimer	Francois Brisebois	Initiate	Outperform	$16
—	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$15
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$15

決算: Q3 2026に発表されました。期中月 11 9thに決算が発表されました月 11 9th マーケットオープン前。

M&A: Ellodi Pharmaceuticals sold assets to Abeona Therapeutics (ABEO) on Monday, November 9, 2026 for $30M

Abeona Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Abeona Therapeutics (ABEO) Stock Price Target 2026

Latest Upgrades and Downgrades for Abeona Therapeutics Stock

Abeona Therapeutics (ABEO) Stock Price Target 2026

Latest Upgrades and Downgrades for Abeona Therapeutics Stock

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Abeona Therapeutics (ABEO) Stock Price Target 2026

Latest Upgrades and Downgrades for Abeona Therapeutics Stock

Abeona Therapeutics (ABEO) Stock Price Target 2026

Latest Upgrades and Downgrades for Abeona Therapeutics Stock

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PROCantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRORoth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PROOppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PROCantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRORoth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PROOppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target